Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-HPV biological protein is a topical viral entry inhibitor developed as a physical barrier and targeted binder to human papillomavirus (HPV). Its principal component is acid anhydrated bovine beta lactoglobulin. The product is designed to block HPV infection by binding directly to the virus and preventing its entry into host cells. It has demonstrated efficacy in controlling infection from various HPV subtypes, with reported negative conversion rates of up to 78.3% at three months and no significant adverse reactions observed in clinical use[1][2]. This product represents a non-vaccine approach for the prevention or adjunctive management of HPV infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-HPV biological protein.